OrthoPreserve

Executive Summary

OrthoPreserve is a private medical device company focused on developing a first-of-its-kind artificial meniscus implant to address persistent knee pain and restore function in patients with meniscus injuries. The implant aims to prevent joint degeneration that leads to osteoarthritis, offering a potential solution for a large unmet need. Currently, the company is advancing its technology through pre-clinical development, targeting first-in-human clinical trials. Given the early-stage nature, the path to commercialization involves significant regulatory, clinical, and manufacturing hurdles. However, if successful, the product could transform the treatment paradigm for meniscus injuries, reducing the progression to knee replacement. The company is privately held and has not disclosed funding or valuation details, suggesting limited public information.

Upcoming Catalysts (preview)

• TBDCompletion of key pre-clinical studies (e.g., large animal model)60% success
• TBDSubmission of Investigational Device Exemption (IDE) or equivalent regulatory filing40% success
• TBDSeries A or B financing round to fund clinical development50% success